ReviewProgress in neuro-psychopharmacology & biological psychiatry2011
Genome-wide association studies of antidepressant outcome: a brief review.
Review in Progress in neuro-psychopharmacology & biological psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Genetic variability in glutamic acid decarboxylase genes: associations with post-traumatic seizures after severe TBI.Epilepsy research · 2013Trial
- Trial
- Trial
- Genetic predisposition to unwanted side effects under antidepressants and antipsychotics: a molecular-genetic study of 902 patients over 6 weeks.European archives of psychiatry and clinical neuroscience · 2026Article
- Genetic determinants of antidepressant and antipsychotic drug response.European archives of psychiatry and clinical neuroscience · 2025Article
- Therapeutic Targets and Molecular Mechanisms of Calycosin in the Treatment of Depression: Insights From Chronic Mild Stress Animal Models.CNS neuroscience & therapeutics · 2025Article
- Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder.Frontiers in psychiatry · 2020Article
- Systems genetics analysis of pharmacogenomics variation during antidepressant treatment.The pharmacogenomics journal · 2018Article
- A Preliminary Study of Genetic Variation in the Dopaminergic and Serotonergic Systems and Genome-wide Additive Genetic Effects on Depression Severity and Treatment Response.Clinical psychological science : a journal of the Association for Psychological Science · 2017Article
- Pharmacogenetics and Imaging-Pharmacogenetics of Antidepressant Response: Towards Translational Strategies.CNS drugs · 2016Review
- Purine and pyrimidine metabolism: Convergent evidence on chronic antidepressant treatment response in mice and humans.Scientific reports · 2016Article
- Identifying genetic loci affecting antidepressant drug response in depression using drug-gene interaction models.Pharmacogenomics · 2016Review
- A genome-wide association study of antidepressant response in Koreans.Translational psychiatry · 2015Article
- Pharmacogenetics of major depressive disorder: top genes and pathways toward clinical applications.Current psychiatry reports · 2015Review
- The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response.Translational psychiatry · 2015Article
- From pharmacogenetics to pharmacogenomics: the way toward the personalization of antidepressant treatment.Canadian journal of psychiatry. Revue canadienne de psychiatrie · 2014Review
- Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder: genome-wide associations and functional genomics.The pharmacogenomics journal · 2013Article
- Exploring the effects of polymorphisms on cis-regulatory signal transduction response.Trends in molecular medicine · 2013Review
- Personalized medicine in major depressive disorder -- opportunities and pitfalls.Metabolism: clinical and experimental · 2013Review
- Gene expression profiles associated with depression in patients with chronic hepatitis C (CH-C).Brain and behavior · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Genome-wide association studies (GWAS) of antidepressant treatment outcome have been at the forefront of psychiatric pharmacogenetics. Such studies may ultimately help match medications with patients, maximizing efficacy while minimizing adverse effects. The hypothesis-free approach of the GWAS has the advantage of interrogating genes that otherwise would have not been considered as candidates due to our limited understanding of their function, and may also uncover important regulatory variation within the large regions of the genome that do not contain protein-coding genes. Three independent samples have so far been studied using a genome-wide approach: The Sequenced Treatment Alternatives to Relieve Depression sample (STAR*D) (n=1953), the Munich Antidepressant Response Signature (MARS) sample (n=339) and the Genome-based Therapeutic Drugs for Depression (GENDEP) sample (n=706). None of the studies reported results that achieved genome-wide significance, suggesting that larger samples and better outcome measures will be needed. This review discusses the published GWAS studies, their strengths, limitations, and possible future directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.